MARKET

TCRT

TCRT

Ziopharm Oncolgy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4977
+0.0161
+3.34%
After Hours: 0.4977 0 0.00% 16:00 05/20 EDT
OPEN
0.4800
PREV CLOSE
0.4816
HIGH
0.5193
LOW
0.4500
VOLUME
1.03M
TURNOVER
0
52 WEEK HIGH
3.730
52 WEEK LOW
0.4053
MARKET CAP
107.48M
P/E (TTM)
-1.3547
1D
5D
1M
3M
1Y
5Y
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from mid-cap companies.
Benzinga · 4d ago
BRIEF-Alaunos Therapeutics Reports Q1 Loss Per Share $0.05
reuters.com · 4d ago
Alaunos Therapeutics Q1 EPS $(0.05) Beats $(0.07) Estimate
Alaunos Therapeutics (NASDAQ:TCRT) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. This is a 50 percent increase over losses of $(0.10) per share from
Benzinga · 4d ago
Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02
Alaunos Therapeutics press release (NASDAQ:TCRT): Q1 GAAP EPS of -$0.05 beats by $0.02. As of March 31, 2022, Alaunos had approximately $68.3 million in cash and cash equivalents.  The Company
Seekingalpha · 4d ago
Earnings Scheduled For May 16, 2022
  Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand.
Benzinga · 4d ago
Alaunos Therapeutics Q1 2022 Earnings Preview
Alaunos Therapeutics (NASDAQ:TCRT) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.07 Over the last 1 year, TCRT has
Seekingalpha · 05/13 15:00
Notable earnings before Monday's open
BITF, CGEN, CLSN, CMRX, OTCQB:CVSI, GOED, KALA, LTRY, LUNA, MNMD, NOVN, OEG, PLX, PTE, SOHU, SSYS, SYN, SYRS, TCRT, WEJO, WIX, WRBY For Seeking Alpha's full earnings season calendar, click
Seekingalpha · 05/13 14:29
Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop
The recent 27% drop in Alaunos Therapeutics, Inc.'s ( NASDAQ:TCRT ) stock could come as a blow to insiders who...
Simply Wall St. · 05/12 15:48
More
No Data
Learn about the latest financial forecast of TCRT. Analyze the recent business situations of Ziopharm Oncolgy through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TCRT stock price target is 4.300 with a high estimate of 7.50 and a low estimate of 1.500.
High7.50
Average4.300
Low1.500
Current 0.4977
EPS
Actual
Estimate
-0.10-0.08-0.05-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 234
Institutional Holdings: 104.92M
% Owned: 48.58%
Shares Outstanding: 215.95M
TypeInstitutionsShares
Increased
31
6.63M
New
15
537.70K
Decreased
38
15.79M
Sold Out
34
3.75M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Chairman/Executive Director
James Huang
Chief Executive Officer
Kevin Boyle
Chief Financial Officer
Timothy Cunningham
Executive Vice President/General Manager
Eleanor de Groot
Other
Raffaele Baffa
Independent Director
Christopher Bowden
Independent Director
Robert Postma
Independent Director
Mary Thistle
Independent Director
Jaime Vieser
Independent Director
Holger Weis
No Data
No Data
About TCRT
Alaunos Therapeutics, Inc., formerly ZIOPHARM Oncology, Inc., is a clinical stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing immuno-oncology platforms. The Company is engaged in developing technologies that utilize the immune system by employing innovative cell engineering to deliver cell therapies for the treatment of multiple cancer types. It is focused on developing T-cell receptor (TCR), T cell therapies to target neoantigens in solid tumors (TCR-T). The Company's platform Sleeping Beauty is based on the non-viral genetic engineering of immune cells using a transposon/transposase system that engineers T cells outside of the body for subsequent infusion. It targets tumor-related mutations in oncogenic genes, including KRAS, TP53 and EGFR, which are prevalent in gastrointestinal, lung, and gynecological cancers. Its pipeline in cell therapy for oncology consists of Library TCR-T cell therapy and mbIL-15 TCR-T cell therapy.

Webull offers kinds of Alaunos Therapeutics Inc stock information, including NASDAQ:TCRT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TCRT stock methods without spending real money on the virtual paper trading platform.